Ugrás a tartalomra
Merck
Összes fotó(2)

Fontos dokumentumok

569396

Sigma-Aldrich

Staurosporine

from Streptomyces sp., ≥97% (HPLC), liquid, protein kinase inhibitor, Calbiochem

Szinonimák:

InSolution Staurosporine, Streptomyces sp., PKA Inhibitor II, MLCK Inhibitor I

Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez


About This Item

Tapasztalati képlet (Hill-képlet):
C28H26N4O3
CAS-szám:
Molekulatömeg:
466.53
MDL-szám:
UNSPSC kód:
12352200
NACRES:
NA.77

product name

Staurosporine, Streptomyces sp., InSolution, ≥97%, 1 mM solution, protein kinase inhibitor

Minőségi szint

Teszt

≥97% (HPLC)

form

liquid

gyártó/kereskedő neve

Calbiochem®

tárolási körülmény

OK to freeze
protect from light

kiszállítva

wet ice

tárolási hőmérséklet

−70°C

InChI

1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1

Nemzetközi kémiai azonosító kulcs

HKSZLNNOFSGOKW-FYTWVXJKSA-N

Általános leírás

A potent, cell-permeable broad spectrum inhibitor of protein kinases. Inhibits CaM kinase (IC50 = 20 nM), myosin light chain kinase (IC50 = 1.3 nM), protein kinase A (IC50 = 7 nM), protein kinase C (IC50 = 0.7 nM), and protein kinase G (IC50 = 8.5 nM). Also inhibits platelet aggregation induced by collagen or ADP but has no effect on thrombin-induced platelet aggregation. Induces apoptosis in human malignant glioma cell lines. Arrests normal cells at the G1 checkpoint.

Biokémiai/fiziológiai hatások

Cell permeable: yes
Primary Target
PKA
Product competes with ATP.
Reversible: yes
Target IC50: 7 nM, 20 nM, 1.3 nM, 700 pM, 8.5 nM, against protein kinase A , CaM kinase, myosin light chain kinase, protein kinase C, and protein kinase G, respectively

Kiszerelés

Packaged under inert gas

Figyelmeztetés

Toxicity: Irritant (B)

Fizikai forma

A 1 mM (100 µg/214 µl) solution of Staurosporine (Cat. No. 569397) in DMSO.

Feloldás

Following initial thaw, aliquot, purge with inert gas, and freeze (-70°C).

Egyéb megjegyzések

Couldwell, W.T., et al. 1994. FEBS Lett.345, 43.
Nishimura, H. and Simpson, I.A. 1994. Biochem. J.302, 271.
Bruno, S., et al. 1992. Cancer Res.52, 470.
Kiss, Z. and Deli, E. 1992. Biochem. J.288, 853.
Vitale, M.L., et al. 1992. Neuroscience51, 463.
Hoffman, R. and Newland, E.S. 1991. Cancer Chemotherap. Pharmacol.28, 102.
Oka, S., et al. 1986. Agric. Biol. Chem.50, 2723.

Jogi információk

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Tárolási osztály kódja

10 - Combustible liquids

WGK

WGK 1

Lobbanási pont (F)

188.6 °F - closed cup - (Dimethylsulfoxide)

Lobbanási pont (C)

87 °C - closed cup - (Dimethylsulfoxide)


Analitikai tanúsítványok (COA)

Analitikai tanúsítványok (COA) keresése a termék sarzs-/tételszámának megadásával. A sarzs- és tételszámok a termék címkéjén találhatók, a „Lot” vagy „Batch” szavak után.

Már rendelkezik ezzel a termékkel?

Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.

Dokumentumtár megtekintése

Athena Kyrkou et al.
Nature communications, 15(1), 5115-5115 (2024-06-16)
Neurofibromatosis Type II (NFII) is a genetic condition caused by loss of the NF2 gene, resulting in activation of the YAP/TAZ pathway and recurrent Schwann cell tumors, as well as meningiomas and ependymomas. Unfortunately, few pharmacological options are available for
Shuai Guo et al.
British journal of pharmacology, 179(21), 4974-4991 (2022-07-15)
Macrophage-rich atherosclerotic arteries are highly active in glycolysis. PFKFB3, a key glycolytic enzyme, has emerged as a potential therapeutic target in atherosclerosis. Small-molecule inhibitors of PFKFB3, such as 3PO and PFK158, have demonstrated efficacy in hampering atherogenesis in preclinical models.
Erin R Spiller et al.
Frontiers in oncology, 11, 771173-771173 (2022-01-08)
Three-quarters of compounds that enter clinical trials fail to make it to market due to safety or efficacy concerns. This statistic strongly suggests a need for better screening methods that result in improved translatability of compounds during the preclinical testing
Marco Ponzetti et al.
Frontiers in oncology, 12, 983254-983254 (2022-12-23)
Osteosarcoma is the most common primary bone malignancy. The crosstalk between osteosarcoma and the surrounding tumour microenvironment (TME) drives key events that lead to metastasization, one of the main obstacles for definitive cure of most malignancies. Extracellular vesicles (EVs), lipid
Liaisan Arslanbaeva et al.
Redox biology, 51, 102272-102272 (2022-03-08)
Cutaneous melanoma is the deadliest type of skin cancer, although it accounts for a minority of all skin cancers. Oxidative stress is involved in all stages of melanomagenesis and cutaneous melanoma can sustain a much higher load of Reactive Oxygen

Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.

Lépjen kapcsolatba a szaktanácsadással